CD38-GEAR-NK / Coeptis, Vycellix - LARVOL DELTA

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PRNewswire) - "Coeptis Therapeutics Holdings...announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. Coeptis intends to immediately commence its due diligence review of VyGen-Bio's assets....This transaction, if finalized, would expand upon Coeptis' collaboration with VyGen-Bio, which is currently focused on CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma, and CD38-Diagnostic, an in vitro diagnostic tool being developed to help identify cancer patients who may be appropriate candidates for anti-CD38 mAb therapy."

M&A • Hematological Malignancies • Multiple Myeloma • Oncology

Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PRNewswire) - "Coeptis Therapeutics, Inc...announces the formation of its Scientific Advisory Board (SAB), which will contribute key guidance on the advancement of the Company's product portfolio highlighted by CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic, which the company is co-developing with VyGen-Bio, Inc."

Clinical • Oncology

Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related Cancers (PRNewswire) - "Coeptis Therapeutics...announced it has exercised its option to acquire ownership in two technology assets that target CD38 cancers from VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc. These two technology assets will now be co-developed by Coeptis and VyGen-Bio. The technologies, CD38-GEAR-NK, a cell therapy product being developed to protect CD38+ natural killer (NK) cells from destruction by anti-CD38 monoclonal antibodies (mAbs), and CD38-Diagnostic, an in vitro diagnostic tool being developed to help identify cancer patients who may be appropriate candidates for anti-CD38 mAb therapy were both discovered by scientists at the Karolinska Institutet in Stockholm, Sweden."

Licensing / partnership • Oncology